Proceedings of the Annual Symposium on Regenerative Medicine (PASRM)

Autologous Immune Enhancement therapy for Advanced Carcinoma of Pancreas-A Case Report


1Shrusti Hospital, Chennai, India.
2Deepam Hospital, Chennai, India.
3Nichi-In Centre for Regenerative Medicine, Chennai, India.
4Yamanashi University - Faculty of Medicine, Chuo, Japan.

* Dr. G.M. Sivaraman, MS, MRCS (UK) Consultant General & Laparoscopic Surgeon, Shrushi Hospital, 1 Padmavathy Street, Thirumalai Nagar, Ramapuram, Chennai-600089, India.
E.Mail: gurunathan_mani@rediffmail.com

Published online on 14 Nov 2008

Introduction:

Autologous Immune Enhancement therapy (AIET) is one of the lesser used modality of therapy in our country for advanced cancers. AIET uses patient’s own immune cells such as NK cells and T-Lymphocytes to fight against cancer.

Aim:

To study the effectiveness of AIET in Advanced Carcinoma of pancreas.

Case History:

A 40 years old male was diagnosed with inoperable locally advanced Carcinoma of the head of pancreas when he was investigated for obstructive jaundice. Palliative bypass surgery was done, since his tumor was inoperable. Following his surgery he received 6 cycles of adjuvant chemotherapy and 3 cycles of AIET. After completion of chemotherapy and 2 cycles of AIET therapy his tumor marker decreased significantly with decrease in tumor size. So re-laparotomy was attempted for removal of tumor, which was unsuccessful. After a long gap he received his 3rd cycle of AIET. He was irregular in receiving his AIET treatment. He survived for 18 months after the diagnosis.

Conclusion:

The median life span of patients following diagnosis of advanced Carcinoma of pancreas is usually not more than 3-6 months. Longer survival of our patient could be due to AIET, but we need further studies to prove it. There were no adverse effects encountered due to AIET.